Paying excess dividends is what put GSK into its no growth situation. It should absolutely not increase payouts until it has a good growth pipeline. |
Q3 announcement next week (Wed 30th) .... ;0) |
I have a reasonable holding here. Holding firm and wanting to add if we get to 1400 (or even 1300) Just sitting on my hands at the moment. The markets are nervy. |
Yes the wider markets are dreadful at the moment |
Yes, patience required ahead of the return to 1800p. It was thought that once the litigation was over (especially when the settlements were announced and the price jumped 84p) that this would take place sooner rather than a return to the doldrums of 1400's. |
Still waiting patiently. |
cumnor, Agree totally. Good post. GSK yield currently 4.1% at share price of 1462p |
Market simply demanding better return for shareholders-3.7% wont cut the ice anymore, whatever GSK's prospects. Needs to be 5% to even consider a look in. No more BS from Emma. Given recent history this is no more low risk than the likes of AV, PHNX or even BARC which are starting to look again at shareholder returns. If GSK wants a premium rating then it needs to pay for it. |
At least Emma can't hide behind zantac anymore |
Been a while but back in to see where it goes from here. |
IN @ 1468.825 ..... ;0) |
Well you did warn everyone I suppose :) |
I actually used the dive in recent price to bed and ISA most of mine so every cloud.. |
Added final trance using dividends today |
Not GSK-specific, whole market a sea of red today. |
This is being relentlessly dumped. |
Dive dive dive! 1300 incoming. |
Most UK shares are not responding to anything |
And regular good product/business news, yet share price not responding. |
Zantac issue almost cleared up and for a lot less than feared yet share price not responding. |
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s share price up 63%.
GSK paid $170 million to close a deal that included global rights to WVE-006 in 2022. Wave will wrap up the current study of WVE-006 and then hand over to GSK, which is on the hook for up to $525 million in milestones, for further development. |
I've bought back in here after quite a while. Looking for diversity and yield - as well as great things. (Time is a great healer .....) Apologies to all longs in advance - my timing is usually poor. |
Any morning gains seem to be routinely reversed with Wall Street opening |
VERY IMPORTANT:
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials - 26 March 2025 assigned as action date for FDA decision.
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
